Profit with us in the 2009 bear market
   

Recent Material Events - Maxygen, Inc (MAXY)

Filing Date Description
2009-09-21 In connection with the Closing, the Company entered into an Asset Contribution Agreement (the “Asset Contribution Agreement”) with Perseid, pursuant to which the Company contributed substantially all of its programs and technology assets in ...
2009-07-17 On July 16, 2009, M.R.C. Greenwood, Ph.D., notified the Chairman of the Board of Directors (the “Board”) of Maxygen, Inc. (the “Company”) that she would not be standing for re-election when her term expires at our 2009 Annual Meet ...
2009-07-01 In connection with the consummation (the “Closing”) of the transaction contemplated by the Joint Venture Agreement (the “Transaction”), the Company will enter into an asset contribution agreement with the Joint Venture, pursuant t ...
2009-03-12 Market for Registrant’s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities 29 Item 6: ...
2008-11-24 On November 18, 2008, the Compensation Committee of the Board of Directors of Maxygen, Inc. (the “Company”) approved annual cash bonuses for the executive officers of the Company for 2008 in the following amounts: ...
2008-09-24 On September 18, 2008, Maxygen, Inc. (the “Company”) entered into a Co-Development and Commercialization Agreement (the “Agreement”) with Astellas Pharma Inc. (“Astellas”) relating to the development and commercializatio ...
2008-07-02 On July 1, 2008, Maxygen, Inc. (the “Company”) and its wholly owned subsidiaries, Maxygen Holdings Ltd. (“Holdings”) and Maxygen ApS, entered into a Technology Transfer Agreement (the “Technology Transfer Agreement”) wit ...
2008-06-13 An update regarding certain patent matters relating to the Company’s MAXY-G34 product candidate, which has been designed to be an improved version of long-acting G-CSF for the treatment of neutropenia and is currently in Phase II clinical trials ...
   
 
Home > Companies > Maxygen, Inc > Recent Material Events